ValuEngine Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) to Sell

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday, June 7th, ValuEngine reports.

Several other analysts also recently weighed in on the stock. BidaskClub downgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 25th. Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $396.00 to $340.00 and set a “neutral” rating for the company in a research note on Thursday, May 23rd. Oppenheimer lifted their price target on shares of Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the company an “outperform” rating in a research note on Thursday, February 7th. Jefferies Financial Group decreased their price target on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in a research note on Wednesday, April 17th. Finally, Cantor Fitzgerald decreased their price target on shares of Regeneron Pharmaceuticals from $441.00 to $405.00 and set a “neutral” rating for the company in a research note on Monday, May 13th. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average price target of $395.78.

NASDAQ REGN traded up $2.33 during trading on Friday, hitting $313.00. The stock had a trading volume of 1,498,962 shares, compared to its average volume of 836,992. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.58 and a quick ratio of 3.78. The stock has a market cap of $33.95 billion, a PE ratio of 15.81, a price-to-earnings-growth ratio of 1.46 and a beta of 1.13. Regeneron Pharmaceuticals has a one year low of $295.27 and a one year high of $442.00. The firm’s 50 day moving average price is $308.61.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $5.24 by ($0.79). The firm had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.76 billion. Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the business earned $4.67 EPS. On average, sell-side analysts expect that Regeneron Pharmaceuticals will post 18.37 EPS for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the transaction, the director now directly owns 11,323 shares of the company’s stock, valued at $3,464,045.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Neil Stahl sold 9,853 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the completion of the transaction, the executive vice president now directly owns 47,450 shares in the company, valued at $14,507,363. The disclosure for this sale can be found here. Insiders own 11.84% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Regeneron Pharmaceuticals by 1.9% in the first quarter. BlackRock Inc. now owns 6,042,908 shares of the biopharmaceutical company’s stock worth $2,481,339,000 after purchasing an additional 113,683 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock valued at $2,325,220,000 after buying an additional 75,868 shares during the last quarter. FMR LLC grew its holdings in shares of Regeneron Pharmaceuticals by 6.6% during the fourth quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock valued at $1,997,245,000 after buying an additional 330,875 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock valued at $402,138,000 after buying an additional 78,143 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 3.7% during the first quarter. American Century Companies Inc. now owns 1,041,044 shares of the biopharmaceutical company’s stock valued at $427,473,000 after buying an additional 37,573 shares during the last quarter. 66.91% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Why do companies issue stock splits?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.